StoxApollo Hospitals Enterprise vs Aurobindo Pharma: share price & financials comparison
NSE: APOLLOHOSP vs AUROPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Apollo Hospitals Enterprise vs Aurobindo Pharma at a glance
Apollo Hospitals Enterprise (APOLLOHOSP) has a market capitalisation of ₹1,22,604 Cr, against ₹1,04,907 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Aurobindo Pharma has returned +58.7%, compared with +9.2% for Apollo Hospitals Enterprise. On valuation, Aurobindo Pharma trades at a lower P/E of 26.3 versus 54.7. Apollo Hospitals Enterprise earns a higher return on equity (21.1% vs 10.1%). Aurobindo Pharma comes out ahead on size, valuation, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Apollo Hospitals Enterprise leads on 5 and Aurobindo Pharma on 13. On StoxGud's 10-point checklist, Apollo Hospitals Enterprise scores 7/10 and Aurobindo Pharma scores 8/10.
| Metric | Apollo Hospitals Enterprise | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,22,604 Cr | ₹1,04,907 Cr |
| Revenue (latest FY) | ₹25,228 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹1,942 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 54.7 | 26.3 |
| P/B | 11.56 | 2.66 |
| Dividend yield | 0.24% | 0.22% |
| Profitability | ||
| Return on equity | 21.1% | 10.1% |
| Net profit margin | 8.1% | 10.8% |
| Operating margin | 15.4% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | +20.8% | +23.9% |
| Net profit growth (YoY) | +32.0% | +32.7% |
| Revenue CAGR (multi-year) | +19.0% | +6.3% |
| Financial health | ||
| Debt to equity | 0.53 | 0.21 |
| Momentum | ||
| 1-month return | +8.3% | +8.2% |
| 1-year return | +9.2% | +58.7% |
| 3-year CAGR | +17.8% | +23.0% |
| 5-year CAGR | +10.9% | +21.3% |
| 10-year CAGR | +21.8% | +9.5% |
| Distance from 52W high | -6.0% | -1.7% |
| Technicals | ||
| RSI (14) | 75 | 86 |
| Price vs 200-day avg | +4.6% | +22.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Apollo Hospitals Enterprise | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Apollo Hospitals Enterprise or Aurobindo Pharma?
Apollo Hospitals Enterprise has a market cap of ₹1,22,604 Cr and Aurobindo Pharma has a market cap of ₹1,04,907 Cr as of 13 Nov 2026.
Which has a lower P/E, Apollo Hospitals Enterprise or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Apollo Hospitals Enterprise trades at 54.7 and Aurobindo Pharma at 26.3.
Which gave better returns in the last year, Apollo Hospitals Enterprise or Aurobindo Pharma?
Aurobindo Pharma did better: Apollo Hospitals Enterprise returned +9.2% and Aurobindo Pharma returned +58.7% over one year.
What is the difference between Apollo Hospitals Enterprise and Aurobindo Pharma?
Both are NSE-listed companies in Healthcare. Apollo Hospitals Enterprise is about 1.2 times the size of Aurobindo Pharma by market cap. In the latest financial year Apollo Hospitals Enterprise reported revenue of ₹25,228 Cr and Aurobindo Pharma ₹33,653 Cr. Operating margin is 15.4% for Apollo Hospitals Enterprise and 20.5% for Aurobindo Pharma. Debt to equity is 0.53 for Apollo Hospitals Enterprise and 0.21 for Aurobindo Pharma.
Which is better, Apollo Hospitals Enterprise or Aurobindo Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Apollo Hospitals Enterprise leads on 5 and Aurobindo Pharma on 13. Aurobindo Pharma is ahead on size, valuation, profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Apollo Hospitals Enterprise scores 7/10 and Aurobindo Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.